Literature DB >> 3135875

Medical management of fibroids.

D T Baird1, C P West.   

Abstract

Mesh:

Substances:

Year:  1988        PMID: 3135875      PMCID: PMC2546081          DOI: 10.1136/bmj.296.6638.1684

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  15 in total

1.  Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.

Authors:  D L Healy; S R Lawson; M Abbott; D T Baird; H M Fraser
Journal:  J Clin Endocrinol Metab       Date:  1986-09       Impact factor: 5.958

2.  Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist.

Authors:  A J Friedman; R L Barbieri; B R Benacerraf; I Schiff
Journal:  Fertil Steril       Date:  1987-10       Impact factor: 7.329

3.  Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women.

Authors:  W H Matta; R W Shaw; R Hesp; D Katz
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-13

4.  Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women.

Authors:  R Lindsay; D M Hart; D Purdie; M M Ferguson; A S Clark; A Kraszewski
Journal:  Clin Sci Mol Med       Date:  1978-02

5.  Goserelin therapy before surgery for uterine fibroids.

Authors:  M A Lumsden; C P West; D T Baird
Journal:  Lancet       Date:  1987-01-03       Impact factor: 79.321

6.  Induction of degenerative changes in uterine myomas by high-dosage progestin therapy.

Authors:  J W Goldzieher; M Maqueo; L Ricaud; J A Aguilar; E Canales
Journal:  Am J Obstet Gynecol       Date:  1966-12-15       Impact factor: 8.661

Review 7.  Clinical applications of LHRH analogues.

Authors:  H M Fraser; D T Baird
Journal:  Baillieres Clin Endocrinol Metab       Date:  1987-02

8.  Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen, antiprogesterone.

Authors:  E M Coutinho; G A Boulanger; M T Gonçalves
Journal:  Am J Obstet Gynecol       Date:  1986-10       Impact factor: 8.661

9.  Risk factors for uterine fibroids: reduced risk associated with oral contraceptives.

Authors:  R K Ross; M C Pike; M P Vessey; D Bull; D Yeates; J T Casagrande
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-09

10.  Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.

Authors:  C P West; M A Lumsden; S Lawson; J Williamson; D T Baird
Journal:  Fertil Steril       Date:  1987-07       Impact factor: 7.329

View more
  1 in total

Review 1.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.